Gene editing-based method of attenuating the beta-amyloid pathway
Described herein are CRISPR/Cas9 constructs designed for the C-terminal truncation of human amyloid precursor protein (APP) as well as methods of making and using such a construct. A Cas9 nuclease/gRNA ribonucleoprotein directs cleavage of an APP gene to provide a C-terminal truncated APP having a length of 659, 670, 676, or 686 amino acids, relative to the human or mouse APP sequence.
1. A method of treating Alzheimer's disease (AD) caused by formation of amyloid plaques composed of amyloid beta (AB) peptides, wherein the method comprises the steps of
a) obtaining a gene-editing construct specific for the amyloid precursor protein (APP), wherein the gene-editing construct facilitates truncation of the APP C-terminus when combined with a Cas9 nuclease, and
b) delivering the gene-editing construct and a construct encoding the Cas9 nuclease to a patient in need of AD therapy, wherein the APP molecule is truncated and production of AB peptides is decreased in the patient's brain, wherein the truncation of the APP C-terminus occurs at an APP residue selected from the group consisting of 659, 670, 676, and 686 relative to SEQ ID NO: 12 (human) or SEQ ID NO: 14 (mouse).
2. The method of claim 1 , wherein the gene-editing construct comprises a gRNA sequence selected from the group consisting of SEQ ID Nos: 1-10.
3. The method of claim 1 , wherein the gene-editing construct and the construct encoding the Cas9 nuclease are delivered in a composition comprising an adeno-associated viral vector and a nanocarrier delivery vehicle.
4. The method of claim 3 , wherein the composition is delivered intravenously or intrathecally.
5. A method of reducing the formation of amyloid plaques in a patient's brain, wherein the plaques comprise amyloid beta (AB) peptides, the method comprises the steps of
a) obtaining a gene-editing construct specific for the amyloid precursor protein (APP), wherein the gene-editing construct facilitates truncation of the APP C-terminus when combined with a Cas9 nuclease, and
b) delivering the gene-editing construct and a construct encoding the Cas9 nuclease to a patient in need of AD therapy, wherein the APP molecule is truncated and production of AB peptides is decreased in the patient's brain, wherein the truncation of the APP C-terminus occurs at an APP residue from the group consisting of 659, 670, 676, and 686 relative to SEQ ID NO: 12 (human) or SEQ ID NO: 14 (mouse).
6. The method of claim 5 , wherein the gene-editing construct comprises a gRNA sequence selected from the group consisting of SEQ ID NOs: 1-10.
7. The method of claim 5 , wherein the gene-editing construct and the construct encoding the Cas9 nuclease are delivered in a composition comprising an adeno-associated viral vector and a nanocarrier delivery vehicle.
8. The method of claim 5 , wherein the composition is delivered intravenously or intrathecally.
9. The method of claim 1 , wherein the gene-editing construct specific for the amyloid precursor protein (APP) comprises a sequence encoding a gRNA specific to amyloid precursor protein (APP), and wherein a Cas9 nuclease/gRNA ribonucleoprotein directs cleavage of the APP gene.
10. The method of claim 5 , wherein the gene-editing construct specific for the amyloid precursor protein (APP) comprises a sequence encoding a gRNA specific to amyloid precursor protein (APP), and wherein a Cas9 nuclease/gRNA ribonucleoprotein directs cleavage of the APP gene.